ClinicalTrials.gg
Active, not recruitingNCT04583774Updated Aug 3, 2026

Developing an EEG Paradigm to Study Prediction Error in Anorexia Nervosa

An interventional study of Prediction error tasks in Anorexia Nervosa, sponsored by University of California, San Diego. Active, not recruiting at 1 site in United States. Open to female participants aged 11 Years to 17 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by University of California, San Diego · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
47
Allocation
Non-randomized
Ages
11 Years to 17 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Anorexia Nervosa by University of California, San Diego — 5 open to participants now, 7 under way, none of them phase 3. Anorexia Nervosa · University of California, San Diego.

Enrollment
5th of 14
47 · median 35
Started
2021
with 1 other
No phase
11 of 19
3 open now
Registered
9th of 19
by date

Among the 19 studies in Anorexia Nervosa by University of California, San Diego, this one is the 5th largest by enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2021, is one of 11 with no phase, and was the 9th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

5 of the 19 studies in Anorexia Nervosa by University of California, San Diego are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 11 Years to 17 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Anorexia Nervosa by University of California, San Diego, or all of them as a file.
02

Study summary

Adolescent anorexia nervosa (AN) is an eating disorder associated with intense fear of weight gain, food refusal, and severe weight loss. AN is the third most common chronic illness among adolescent females with a mortality rate 12 times higher than expected for females 15-24 years old. Little is known about biomarkers in adolescent AN.

Neuroimaging studies have repeatedly suggested altered reward processing in AN including in studies using the dopamine associated prediction error (PE) model. The brain PE response is elicited during unexpected receipt or omission of reward stimuli and thought to reflect the functionality of brain dopamine circuits. This is an important research direction as the dopamine system can be manipulated pharmacologically. In ill and recovered adult AN, unexpected or randomly applied sucrose taste stimuli evoked higher insular and striatal responses and unexpected omission or receipt of monetary or taste reward was associated with a similar response pattern in adolescent AN. PE was also inversely related to weight gain in treatment. Thus, PE brain response promises to be an important biological marker for adolescent AN with predictive value for treatment outcome. However, functional brain imaging is costly, prohibitive for instance for individuals with braces or other metal in their body and only available at certain centers. In order to study PE in AN in larger scale studies, a more practical approach and method need to be developed. In this application, we will use the exploratory/developmental R21 mechanism to develop a study protocol using electroencephalography (EEG) to study PE signals in adolescent AN. Recent studies in healthy individuals support that this is a valid approach.

Our primary goal for this study is to test the feasibility of the use of EEG for prediction error and reversal learning studies in AN with the longer term goal of replacing fMRI that is costly and associated with frequent participant rule out.

In Aim 1. we test the feasibility of adapting a computational taste PE reinforcement learning paradigm from fMRI to EEG in adolescents with AN and healthy controls. We expect that we will find internal consistency of taste PE brain response across fMRI and EEG in adolescents with AN as well as age-matched healthy controls, within each group. We further expect that we will find preliminary evidence that the EEG paradigm will be able to discriminate the AN group from the HC adolescents based on feedback related negativity and higher event-related potential amplitudes, which will correlate with fMRI PE brain response.

In Aim 2., we test whether a monetary PE paradigm will show similar EEG brain response as taste PE in Aim 1. to establish the generalizability of EEG taste and non-taste paradigms.

The development of an EEG based reward PE study paradigm will enable us in the future to conduct large-scale studies that will be less costly and independent from brain imaging centers that are only available to a small subset of adolescents with AN.

03

Conditions studied

  • Anorexia Nervosa

Browse trials for

04

Who can participate

Ages eligible
11 Years to 17 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy Controls

  • Females ages 11 - 17 years
  • Healthy body weight between 90 and 110 % average body weight.
  • Edinburgh Handedness Inventory Revised (EHI-R) LQ* score > +200
  • English is primary language spoken

Restricting Type Anorexia Nervosa

  • Females ages 11 - 17 years
  • Diagnostic criteria. Current diagnosis of AN, including being underweight below 17.5 (BMI, kg/m2), will have a severe fear of weight gain, body image distortion and absence of the menstrual cycle over three consecutive months (if applicable).
  • First 1-2 weeks in treatment at The University of California San Diego Eating Disorders Center for Treatment and Research or Rady Children's Hospital San Diego Medical Behavioral Unit.
  • Restricting subtype, that is without binge/purge behaviors
  • Edinburgh Handedness Inventory Revised (EHI-R) LQ* score > +200
  • English is primary language spoken

Exclusion criteria

Exclusion Criteria:

Healthy Controls

  • Current pregnancy or breast feeding within last 3 months
  • Illiterate/Blind individuals
  • First degree relative with current or past eating disorder
  • Current Medications other than BCP or IUD
  • Past or present Axis I psychiatric disorder including substance or alcohol use disorder as determined through PI interview and MINI-Kid clinical interview
  • Major Medical illness (as determined through medical history in bioscreen and PI interview) such as:

    • Conditions that are life threatening:

      • cancer
      • heart disease
      • stroke
      • /AIDS
      • Seizure Disorders
    • Conditions that are life threatening Conditions that cause serious disability without necessarily being life threatening:

      • stroke
      • closed head or spinal cord injuries
      • mental retardation
      • congenital malformations.
    • Conditions that cause significant pain or discomfort that can cause serious interruptions to life activities:

      • severe allergies
      • migraine
      • arthritis
      • sickle cell disease
    • Conditions that require major commitments of time and effort from care-givers for a substantial period of time:

      • mobility disorders
      • blindness
      • Alzheimer's disease and other dementias
      • paraplegia or quadriplegia
      • Down's syndrome
      • depression
    • Conditions that may require frequent monitoring:

      • diabetes
      • conditions requiring anticoagulation treatment
      • severe asthma
      • severe allergies
      • schizophrenia and other psychotic illnesses.
    • Conditions that predict or are associated with severe consequences:

      • hypertension (associated with heart disease)
      • depression (associated with suicide)
      • diabetes (associated with blindness, kidney failure)
      • alcohol and other substance abuse (associated with intentional and unintentional injuries).
  • Recent history of suspected substance abuse or a lifetime history of psychostimulant abuse and/or dependence
  • Metal implants or braces (as determined through fMRI screening form)

Anorexia Nervosa

  • Pregnancy or breast feeding within last 3 months
  • Lifetime history of bipolar disorder or psychosis
  • Illiterate/Blind individuals
  • Use of an anti-psychotic or other dopamine acting medication including stimulants within the past week at time of MRI
  • Recent history of substance abuse or dependence (within the last month)
  • Major Medical illness (as determined through medical history in bioscreen and PI interview) such as:

    • Conditions that are life threatening:

      • cancer
      • heart disease
      • stroke
      • HIV/AIDS
      • Seizure Disorders
    • Conditions that are life threatening Conditions that cause serious disability without necessarily being life threatening:

      • stroke
      • closed head or spinal cord injuries
      • mental retardation
      • congenital malformations.
    • Conditions that cause significant pain or discomfort that can cause serious interruptions to life activities:

      • severe allergies
      • migraine
      • arthritis
      • sickle cell disease
    • Conditions that require major commitments of time and effort from care-givers for a substantial period of time:

      • mobility disorders
      • blindness
      • Alzheimer's disease and other dementias
      • chronic obstructive pulmonary disease
      • paraplegia or quadriplegia
      • Down's syndrome
    • Conditions that may require frequent monitoring:

      • diabetes
      • conditions requiring anticoagulation treatment
      • severe asthma
      • severe allergies
      • schizophrenia and other psychotic illnesses.
    • Conditions that predict or are associated with severe consequences:

      • hypertension (associated with heart disease)
      • diabetes (associated with blindness, kidney failure)
      • alcohol and other substance abuse (associated with intentional and unintentional injuries) within the last month
  • Metal implants or braces (as determined through fMRI screening form)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
47 participants (actual)

Study arms

  • Other
    Anorexia Nervosa Group

    Participants with anorexia nervosa

    Other: Prediction error tasks

  • Other
    Healthy Control Group

    Participants who are considered to be healthy controls

    Other: Prediction error tasks

Interventions

  • OtherPrediction error tasks

    The intervention involves two tasks, one that involves taste stimuli and another that involves monetary stimuli, and test their impact o brain response in electro encephalography (EEG) and functional magnetic resonance imaging (fMRI)

06

What researchers measure

Primary outcomes

  1. Correlation between Reward Prediction Error Brain Response using functional Magnetic Resonance Imaging (fMRI) and Electroencephalography (EEG)

    Study participants will undergo an fMRI session during which they perform a taste reward prediction error paradigm. Blood oxygen-level dependent (BOLD) functional activity will be acquired during the task. The prediction error signal will be modeled based on trial sequence. The same individuals will perform the prediction error task during EEG. fMRI and EEG results for brain regions will be compared and tested for correlations between modalities.

    Time frame: Immediate during brain scanning

  2. Reward Prediction Error Brain Response using Electroencephalography (EEG) to separate healthy controls from individuals with anorexia nervosa.

    We will test whether regional brain EEG recordings from the taste prediction error paradigm in Outcome 1 can distinguish individuals with anorexia nervosa from healthy controls.

    Time frame: Immediate during brain scanning

  3. Monetary Reward Prediction Error Brain Response using EEG will show similar regional brain response compared to taste prediction error response.

    Study participants will undergo an EEG session during which they perform a monetary reward prediction error paradigm. The results will be compared to the taste paradigm results from Outcome 1.

    Time frame: Immediate during brain scanning

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No plan to share IPD

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2021 (actual). Primary completion is estimated for Dec 2026, 70 months after the start.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 70 months is above that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2020
First posted
Oct 12, 2020
StartActual
Feb 9, 2021
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04583774
Responsible party
Guido Frank (Professor, University of California, San Diego) — Principal investigator
First posted
Oct 12, 2020
Start date
Feb 9, 2021
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

Guido Frank, MD
principal investigator · University of California, San Diego

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion